Gilead(US:GILD) ZACKSยท2025-10-22 23:01Company Performance - Gilead Sciences (GILD) closed at $121.46, reflecting a -2.11% change from the previous day, underperforming the S&P 500's loss of 0.53% [1] - Prior to this trading session, Gilead's shares had increased by 8.46%, outperforming the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13% [1] Upcoming Earnings - Gilead Sciences is set to disclose its earnings on October 30, 2025, with an anticipated EPS of $2.15, representing a 6.44% increase from the same quarter last year [2] - The consensus estimate for quarterly revenue is $7.46 billion, which is a decrease of 1.14% compared to the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict earnings of $8.07 per share and revenue of $28.78 billion, indicating increases of +74.68% and +0.08% respectively from the prior year [3] - Recent changes to analyst estimates for Gilead Sciences reflect near-term business trends, with positive revisions indicating analysts' confidence in the company's performance [3][4] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 15.38, which is lower than the industry average Forward P/E of 20.42, suggesting a valuation discount [6] - The company also has a PEG ratio of 0.85, compared to the industry average PEG ratio of 1.67, indicating favorable growth expectations relative to its valuation [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [8] - Strong industry rankings correlate with performance, as the top 50% of rated industries tend to outperform the bottom half by a factor of 2 to 1 [8]